An overview: CRISPR/Cas-based gene editing for viral vaccine development

Bhujbal, Santosh S.; Bhujbal, Rushikesh; Giram, Prabhanjan S.

doi:10.1080/14760584.2022.2112952

Cited by 4 publications

(4 citation statements)

References 182 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast, the CRISPR/Cas system can produce multivalent vaccines that offer long-lasting and protective immunity and have tremendous potential in generating specific B-cells to produce highly potent antibodies against current and future emerging strains of viruses ( Figure 5 A). The CRISPR/Cas system has been used to produce recombinant vaccines for various organisms, such as viruses [ 289 ], bacteria [ 290 ], fungi [ 291 ], plants [ 292 ], and animal cells [ 293 ]. Cas systems can be used to knockout or insert new genes in the cells or viral vector to develop a new generation of vaccines.…”

Section: Crispr/cas and Vaccine Developmentmentioning

confidence: 99%

“…Studies have shown that the HIV genome can be removed using CRISPR/Cas for sterilizing the cure of HIV, which will benefit millions of people and prevent disease transmission. Due to high specificity and efficacy, the CRISPR/Cas system has been utilized to generate recombinant vaccines and B-cell engineering to produce more effective vaccines [ 289 , 326 ]. CRISPR/Cas system-based genetic engineering can be used to increase the vaccine yield by removing negative factors that suppress the host immune system.…”

Section: Conclusion and Future Directionmentioning

confidence: 99%

“…CRISPR/Cas system-based genetic engineering can be used to increase the vaccine yield by removing negative factors that suppress the host immune system. Notably, CRISPR/Cas-engineered vaccines are more effective and require a lower cost and time to generate than conventional vaccines [ 288 , 289 ].…”

Section: Conclusion and Future Directionmentioning

confidence: 99%

See 2 more Smart Citations

Precision in Action: The Role of Clustered Regularly Interspaced Short Palindromic Repeats/Cas in Gene Therapies

Banda,

Impomeni,

Singh

et al. 2024

Vaccines

View full text Add to dashboard Cite

Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated enzyme-CAS holds great promise for treating many uncured human diseases and illnesses by precisely correcting harmful point mutations and disrupting disease-causing genes. The recent Food and Drug Association (FDA) approval of the first CRISPR-based gene therapy for sickle cell anemia marks the beginning of a new era in gene editing. However, delivering CRISPR specifically into diseased cells in vivo is a significant challenge and an area of intense research. The identification of new CRISPR/Cas variants, particularly ultra-compact CAS systems with robust gene editing activities, paves the way for the low-capacity delivery vectors to be used in gene therapies. CRISPR/Cas technology has evolved beyond editing DNA to cover a wide spectrum of functionalities, including RNA targeting, disease diagnosis, transcriptional/epigenetic regulation, chromatin imaging, high-throughput screening, and new disease modeling. CRISPR/Cas can be used to engineer B-cells to produce potent antibodies for more effective vaccines and enhance CAR T-cells for the more precise and efficient targeting of tumor cells. However, CRISPR/Cas technology has challenges, including off-target effects, toxicity, immune responses, and inadequate tissue-specific delivery. Overcoming these challenges necessitates the development of a more effective and specific CRISPR/Cas delivery system. This entails strategically utilizing specific gRNAs in conjunction with robust CRISPR/Cas variants to mitigate off-target effects. This review seeks to delve into the intricacies of the CRISPR/Cas mechanism, explore progress in gene therapies, evaluate gene delivery systems, highlight limitations, outline necessary precautions, and scrutinize the ethical considerations associated with its application.

show abstract

Section: Crispr/cas and Vaccine Developmentmentioning

confidence: 99%

Section: Conclusion and Future Directionmentioning

confidence: 99%

See 1 more Smart Citation

Precision in Action: The Role of Clustered Regularly Interspaced Short Palindromic Repeats/Cas in Gene Therapies

Banda,

Impomeni,

Singh

et al. 2024

Vaccines

View full text Add to dashboard Cite

show abstract

“…Vaccines have been proven to be the most effective weapon for controlling and preventing viral diseases . However, extermination of SVCV-infected fish is still the basic measure for controlling SVCV . There is currently no commercially available vaccine against SVCV.…”

Section: Introductionmentioning

confidence: 99%

Rationally Designed Self-Assembling Nanovaccines Elicit Robust Mucosal and Systemic Immunity against Rhabdovirus

Zhang,

Zhao,

Jia

et al. 2023

ACS Appl. Mater. Interfaces

View full text Add to dashboard Cite

Viral diseases have constantly caused great threats to global public health, resulting in an urgent need for effective vaccines. However, the current viral vaccines often show low immunogenicity. To counter this, we report a smart strategy of a well-designed modular nanoparticle (LSG-TDH) that recapitulates the dominant antigen SG, low-molecular-weight protamine, and tetralysinemodified H-chain apoferritin (TDH). The constructed LSG-TDH nanovaccine could self-assemble into a nanocage structure, which confers excellent mucuspenetrating, cellular affinity, and uptake ability. Studies demonstrate that the LSG-TDH nanovaccine could strongly activate both mucosal and systemic immune responses. Importantly, by immunizing wild-type and TLR2 knockout (TLR2-KO) zebrafish, we found that TLR2 could mediate LSG-TDH-induced adaptive mucosal and systemic immune responses by activating antigenpresenting cells. Collectively, our findings offer new insights into rational viral vaccine design and provide additional evidence of the vital role of TLR2 in regulating adaptive immunity.

show abstract

Application of CRISPR–cas-based technology for the identification of tuberculosis, drug discovery and vaccine development

Shi,

Gu,

Long

et al. 2024

Mol Biol Rep

View full text Add to dashboard Cite

An overview: CRISPR/Cas-based gene editing for viral vaccine development

Cited by 4 publications

References 182 publications

Precision in Action: The Role of Clustered Regularly Interspaced Short Palindromic Repeats/Cas in Gene Therapies

Precision in Action: The Role of Clustered Regularly Interspaced Short Palindromic Repeats/Cas in Gene Therapies

Rationally Designed Self-Assembling Nanovaccines Elicit Robust Mucosal and Systemic Immunity against Rhabdovirus

Application of CRISPR–cas-based technology for the identification of tuberculosis, drug discovery and vaccine development

Contact Info

Product

Resources

About